The routine incorporation of NPM1, FLT3 and perhaps CEBPA-DM mutational testing can now be strongly recommended in addition to a standard karyotype evaluation. Patients with normal cytogenetics ...

Gene mutations in acute myeloid leukemia (AML) cells can guide treatment options, and machine learning can rapidly guess the ...

Actinium Pharma inks research pact with Memorial Sloan Kettering to support further clinical expansion of Actimab-A's backbone therapy strategy: New York Saturday, March 22, 2025, ...

The fourth patient, with FLT3-ITD and NPM1 mutations, is dosing in cycle 1 and is not yet eligible for response evaluation. Aptose intends to enroll 18-24 patients in the phase 1/2 clinical trial ...

Actinium Pharmaceuticals (ATNM) has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center to expand ...

The fourth patient, harboring FLT3-ITD and NPM1 mutations, is currently dosing in Cycle 1 and is not yet eligible for response evaluation. Pharmacokinetic (PK) analyses for TUS show plasma levels ...

to predict post-transplant relapse and survival compared to flow cytometry in patients with FLT3-ITD or NPM1 mutated AML. The current collection of manuscripts presents additional original data ...

Risk categorization of AML based on karyotyping of leukemic blasts has become routine. Mutations in NPM1, CCAAT enhancer-binding protein-α (with double-mutations) and FCT3-internal tandem ...